UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 38

Sortiert nach

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

Annals of oncology, 2008-05, Vol.19 (5), p.861-870

2008

Volltextzugriff (PDF)

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Annals of oncology, 2017-11, Vol.28 (11), p.2768-2772

2017

Volltextzugriff (PDF)

Triple-negative breast cancer—current status and future directions

Annals of oncology, 2009-12, Vol.20 (12), p.1913-1927

2009

Volltextzugriff (PDF)

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Annals of oncology, 2014-08, Vol.25 (8), p.1551-1557

2014

Volltextzugriff (PDF)

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

The New England journal of medicine, 2005-10, Vol.353 (16), p.1659-1672

2005

Volltextzugriff (PDF)

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

Annals of oncology, 2015-04, Vol.26 (4), p.688-695

2015

Volltextzugriff (PDF)

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

JNCI : Journal of the National Cancer Institute, 2003-09, Vol.95 (17), p.1320-1329

2003

Volltextzugriff (PDF)

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

JNCI : Journal of the National Cancer Institute, 2006-08, Vol.98 (15), p.1036-1045

2006

Volltextzugriff (PDF)

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

JNCI : Journal of the National Cancer Institute, 2013-07, Vol.105 (14), p.1018-1026

2013

Volltextzugriff (PDF)

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Annals of oncology, 2016-06, Vol.27 (6), p.1035-1040

2016

Volltextzugriff (PDF)

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

Annals of oncology, 2015-10, Vol.26 (10), p.2198-2199

2015

Volltextzugriff (PDF)

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

Annals of oncology, 2014-01, Vol.25 (1), p.75-80

2014

Volltextzugriff (PDF)

MR imaging of cranial nerve lesions using six different high‐resolution T1‐ and T2()‐weighted 3D and 2D sequences

Acta radiologica (1987), 2002-07, Vol.43 (4), p.349-353

2002

Volltextzugriff (PDF)

Lunar phase does not influence surgical quality

European journal of medical research, 2003-09, Vol.8 (9), p.414-418

2003

Volltextzugriff (PDF)

SPIRAL STENT VERSUS STANDARD STENT IN PATIENTS WITH MIDSIZE RENAL STONES TREATED WITH EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY: WHICH STENT WORKS BETTER? A PROSPECTIVE RANDOMIZED TRIAL

The Journal of urology, 2004-09, Vol.172 (3), p.965-966

2004

Volltextzugriff (PDF)

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

European journal of nuclear medicine, 1999-03, Vol.26 (3), p.226

1999

Volltextzugriff (PDF)

Systemic therapy of operable carcinoma of the breast

Zentralblatt für Gynäkologie, 2005, Vol.127 (4), p.207

2005

Volltextzugriff (PDF)

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer : An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

Seminars in oncology, 1997-10, Vol.24 (5), p.S15-44

1997

Volltextzugriff (PDF)

C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy

Verhandlungen der Deutschen Gesellschaft fur Pathologie, 2006, Vol.90, p.177

2006

Volltextzugriff (PDF)

Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy

Verhandlungen der Deutschen Gesellschaft fur Pathologie, 2007, Vol.91, p.187

2007

Volltextzugriff (PDF)

Evidence-based recommendations on primary treatment of carcinomas of the breast

Zentralblatt für Gynäkologie, 2002-05, Vol.124 (5), p.293

2002

Volltextzugriff (PDF)

Metastatic Choriocarcinoma in a Postmenopausal Woman

Gynecologic oncology, 1996-06, Vol.61 (3), p.432-437

1996

Volltextzugriff (PDF)

Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast

Zentralblatt für Gynäkologie, 2002-05, Vol.124 (5), p.284

2002

Volltextzugriff (PDF)

1 – 25 von 38

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(31)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(37)
Tagungsberichte
(1)

Sprache

Englisch
(24)
Deutsch
(14)
Japanisch
(4)

Erscheinungsjahr

n.n

Menü

Weitere Dienste

Einstellungen

Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial

De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel

Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial

Triple-negative breast cancer—current status and future directions

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Safety and efficacy outcomes with erythropoiesis-stimulating agents in patients with breast cancer: a meta-analysis

A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer

Randomized Phase III Trial of Topotecan Following Carboplatin and Paclitaxel in First-line Treatment of Advanced Ovarian Cancer: A Gynecologic Cancer Intergroup Trial of the AGO-OVAR and GINECO

Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial

Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial

Reply to letter to the editor ‘Primum non nocere’ by Templeton and Šeruga

PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel±darbepoetin alfa in primary breast cancer—results at the time of surgery

Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer

MR imaging of cranial nerve lesions using six different high‐resolution T1‐ and T2()‐weighted 3D and 2D sequences

Lunar phase does not influence surgical quality

SPIRAL STENT VERSUS STANDARD STENT IN PATIENTS WITH MIDSIZE RENAL STONES TREATED WITH EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY: WHICH STENT WORKS BETTER? A PROSPECTIVE RANDOMIZED TRIAL

Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

Systemic therapy of operable carcinoma of the breast

Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer : An interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

C-kit expression in high-risk breast cancer subgroup treated with high-dose or conventional dose-dense chemotherapy

Prognostic and predictive impact of protein expression profiling in high risk breast cancer patients treated with high-dose chemotherapy

Evidence-based recommendations on primary treatment of carcinomas of the breast

Metastatic Choriocarcinoma in a Postmenopausal Woman

Evidence-based recommendations on treating locoregional and distant metastases of carcinomas of the breast

Aktive Filter

Suchergebnisse filtern